Ceribell (CBLL) Preferred Stock Liabilities (2023 - 2024)
Ceribell posted quarterly Preferred Stock Liabilities of $988000.0 for Q3 2024, down 99.33% year-on-year from $147.4 million in Q4 2023, and down 99.33% on a QoQ basis from $147.4 million in Q2 2024.
Ceribell (CBLL) has 2 years of Preferred Stock Liabilities data on file, last reported at $988000.0 in Q3 2024.
- For the quarter ending Q3 2024, Preferred Stock Liabilities fell 99.33% year-over-year to $988000.0; the trailing twelve-month figure through Sep 2024 stood at $988000.0 (down 99.33% YoY), and the FY2023 full-year result was $1.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q3 2024 stood at $988000.0, down from $147.4 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $147.4 million in Q3 2023 and bottomed at $988000.0 in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Ceribell | 666.26 Mn | 525.07 Mn | 23.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 988,000.00 |
| Jun 30, 2024 | 147.41 Mn |
| Mar 31, 2024 | 147.41 Mn |
| Dec 31, 2023 | 1.00 Mn |
| Sep 30, 2023 | 147.41 Mn |